BREAST CANCER METASTATIC

This adverse event was reported 10750 times

These drugs are most commonly taken by patients reporting BREAST CANCER METASTATIC:

# Drug Count
0 LETROZOLE 2035
1 LETROZOLE TABLETS 1712
2 FULVESTRANT 1696
3 ESTROGENS, CONJUGATED 1682
4 CONJUGATED ESTROGENS 1680
5 RIBOCICLIB 1678
6 CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE 1505
7 MEDROXYPROGESTERONE ACETATE 1384
8 CAPECITABINE 1248
9 PALBOCICLIB 1077
See all common drugs associated with BREAST CANCER METASTATIC

BREAST CANCER METASTATIC is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE 1505 0.0641
1 RIBOCICLIB 1678 0.0513
2 FULVESTRANT 1696 0.0506
3 EXEMESTANE 849 0.0395
4 VINORELBINE 249 0.0357
5 LETROZOLE TABLETS 1712 0.0350
6 LETROZOLE 2035 0.0326
7 NERATINIB 71 0.0306
8 CONJUGATED ESTROGENS 1680 0.0289
9 ESTROGENS, CONJUGATED 1682 0.0284
See all drugs enriched for association with BREAST CANCER METASTATIC

BREAST CANCER METASTATIC is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Estrogen Receptor Antagonist [EPC] 1706 0.0421
1 Aromatase Inhibitor [EPC] 2855 0.0251
2 HER2/neu Receptor Antagonist [EPC] 1072 0.0143
3 Estrogen [EPC] 2165 0.0116
4 Interleukin-5 Antagonist [EPC] 6 0.0087
5 Endoglycosidase [EPC] 15 0.0081
6 Provitamin D2 Compound [EPC] 215 0.0072
7 Microtubule Inhibitor [EPC] 1121 0.0068
8 Nucleoside Metabolic Inhibitor [EPC] 1353 0.0049
9 Non-Standardized Fungal Allergenic Extract [EPC] 9 0.0042
See all drug classes enriched for association with BREAST CANCER METASTATIC